NCT03252847View on ClinicalTrials.gov

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

November 18, 2021

Study Completion Date

November 18, 2021

Conditions
X-Linked Retinitis Pigmentosa
Interventions
GENETIC

AAV5-RPGR

Single, subretinal administration of AAV5-RPGR

Trial Locations (5)

15213

UPMC Eye Center, Pittsburgh

48105

Kellogg Eye Center, Ann Arbor

02114

Massachusetts Eye and Ear Institute, Boston

LS9 7TF

Leeds Teaching Hospitals NHS Trust, Leeds

Unknown

Moorfields Eye Hospital NHS Foundation Trust, London

Sponsors

Collaborators (1)

Bionical Emas
All Listed Sponsors
collaborator

Syne Qua Non Limited

INDUSTRY

collaborator

Bionical Emas

INDUSTRY

lead

MeiraGTx UK II Ltd

INDUSTRY

NCT03252847 - Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) | Biotech Hunter | Biotech Hunter